| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Darunavir & cobicistat |
| Brand | Rezolsta® |
| Indication | Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. |
| Assessment Process | |
| Rapid review commissioned | 02/12/2014 |
| Rapid review completed | 08/01/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Not Recommended |